Lytenava (Bevacizumab-vikg)

Warnings & Precautions

Endophthalmitis and Retinal Detachments: Intravitreal injections have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique should always be used when administering LYTENAVA.
Increases in Intraocular Pressure: Increases in intraocular pressure have been noted post-injection (up to 60 minutes) while being treated with LYTENAVA. Monitor intraocular pressure prior to and following intravitreal injection with LYTENAVA and manage appropriately .
Thromboembolic Events: Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LYTENAVA clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors.

Common Side Effects

Most common adverse reaction (≥ 4%) reported in patients receiving LYTENAVA was conjunctival hemorrhage (4%).

Pregnancy & Lactation

Pregnancy: Based on the anti-VEGF mechanism of action for bevacizumab products , treatment with LYTENAVA may pose a risk to human embryofetal development. There are no adequate and well-controlled studies of LYTENAVA administration in pregnant women or pregnant animals.

Lactation: There are no data available on the presence of bevacizumab-vikg in human milk, the effects of bevacizumab-vikg on the breastfed infant or the effects of bevacizumab-vikg on milk production/excretion.

Pediatric Use

The safety and effectiveness of LYTENAVA in pediatric patients have not been established.